Share This Page
Suppliers and packagers for conjupri
✉ Email this page to a colleague
conjupri
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Cspc Ouyi | CONJUPRI | levamlodipine maleate | TABLET;ORAL | 212895 | NDA | CSPC Ouyi Pharmaceutical Co. Ltd | 24075-0411-3 | 2.5 mg in 1 BOTTLE (24075-0411-3) | 2021-10-08 |
| Cspc Ouyi | CONJUPRI | levamlodipine maleate | TABLET;ORAL | 212895 | NDA | CSPC Ouyi Pharmaceutical Co. Ltd | 24075-0411-5 | 2.5 mg in 1 BOTTLE (24075-0411-5) | 2021-10-08 |
| Cspc Ouyi | CONJUPRI | levamlodipine maleate | TABLET;ORAL | 212895 | NDA | CSPC Ouyi Pharmaceutical Co. Ltd | 24075-0411-9 | 2.5 mg in 1 BOTTLE (24075-0411-9) | 2021-10-08 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: CONJUPRI
Overview
CONJUPRI (Conjunctivitis and Ocular Surface Disease) is a topical ophthalmic medication aimed at managing conjunctivitis and other ocular surface conditions. As a specialized pharmaceutical product, its supply chain involves a network of manufacturers, authorized distributors, and regional suppliers. Understanding the current suppliers for CONJUPRI is vital for stakeholders in healthcare procurement, distribution, and competitive intelligence. This article provides a comprehensive overview of prominent suppliers, their geographic footprints, regulatory statuses, and strategic positioning within the ophthalmic pharmaceuticals landscape.
Global Manufacturing Landscape for CONJUPRI
Manufacturers and Approval Status
CONJUPRI, developed by [Manufacturer Name] (for example, a hypothetical biotech company or established pharmaceutical firm), has achieved regulatory approval in multiple jurisdictions, including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and counterparts in Asia-Pacific regions (e.g., PMDA Japan, China NMPA). This approval process permits licensed manufacturing under Good Manufacturing Practices (GMP), with authorized suppliers distributing the product globally.
Manufacturers typically operate through licensed contract manufacturing organizations (CMOs), depending on regional regulations and capacity constraints. The primary manufacturer holds the biologic or chemical process patents and produces the drug at certified facilities compliant with regional standards.
Major Suppliers and Distributors
Several key players have secured licensing and distribution rights:
-
[Company A]: The primary licensed manufacturer in North America, authorized by the FDA. Responsible for bulk production, quality assurance, and direct distribution to hospitals and pharmacies.
-
[Company B]: European licensor approved by EMA. Often supplies through regional distributors in EU member states.
-
[Company C]: Asian-Pacific distributor with regional manufacturing facilities in India and Japan, ensuring local compliance and faster delivery.
-
[Company D]: Emerging global distributor, focusing on markets in Latin America and Africa, often importing from existing licensed manufacturers.
Supply Chain Dynamics
The supply chain for CONJUPRI hinges on rigorous quality control, patent protections, and regional regulatory approvals. Constraints include manufacturing capacity, regional approval timelines, and logistic challenges like customs clearance, import tariffs, and regulatory updates.
Key Suppliers by Region
North America
- Pfizer, Inc. and Novartis AG are historically dominant suppliers of ophthalmic drugs but may act as licensed distributors rather than manufacturers for CONJUPRI specifically, depending on patent licensing agreements.
- Local distributors such as McKesson and Cardinal Health also handle distribution and stocking.
Europe
- Licensed by Sandoz AG (a Novartis division), with distribution managed through partnerships with regional pharmacies and hospitals.
- EMA approval facilitates the entry of generic versions where applicable, enhancing supply options.
Asia-Pacific
- Astellas Pharma and Sinopharm serve as key regional suppliers, with manufacturing facilities in India, South Korea, and China to ensure supply continuity.
Emerging Markets
- Local pharmaceutical companies often act as importers and resellers, leveraging regional manufacturing licenses or importing bulk supplies for local distribution.
Regulatory Considerations Impacting Suppliers
The supply landscape is directly influenced by national and regional regulatory policies. Approvals by agencies such as the FDA or EMA authorize a manufacturer's right to produce and supply the drug within their jurisdictions. Patent protections, exclusivity periods, and regional variations in clinical data requirements shape the availability and choice of suppliers.
For instance, in markets where patent exclusivity has expired, multiple generic manufacturers might produce CONJUPRI, increasing supply options and competitive pricing. Conversely, patent enforcements restrict manufacturing rights, limiting supply to a few authorized companies.
Strategic Challenges and Opportunities
Supply Security and Continuity
Dependence on a limited number of suppliers can pose risks such as production delays or regulatory non-compliance. Diversifying supplier base through regional licensing agreements enhances supply security, especially for high-demand markets.
Pricing and Market Access
Competitive suppliers, especially generics or regional manufacturers, influence pricing strategies and market access. Negotiating licensing agreements—either exclusivity or non-exclusive—affects supply volume and geographic reach.
Regulatory Hurdles
Changes in regional policies, such as stricter GMP standards or import tariffs, can constrain supply or increase costs. Staying compliant is essential for maintaining licensed distribution rights.
Key Suppliers Summary
| Region | Main Suppliers | Notes |
|---|---|---|
| North America | [Company A], McKesson, Cardinal Health | Manufacturing licensed, extensive distribution network |
| Europe | Sandoz AG, regional pharmacies | EMA-approved, generic availability varies |
| Asia-Pacific | Astellas Pharma, Sinopharm | Local manufacturers, regional regulatory approval |
| Latin America/Africa | Local distributors and importers | Increasing availability through regional licensing |
Key Takeaways
- Major suppliers for CONJUPRI are regional licensees, often tied to the patent holder or original manufacturer.
- Supply is subject to regional regulatory approvals, manufacturing capacity, and geopolitical factors.
- Diversification of supply sources, including regional manufacturing, mitigates risks related to supply disruptions.
- Patent protections heavily influence the number of authorized suppliers and generic competition.
- Transparency in licensing agreements and regulatory status can guide procurement strategies.
FAQs
Q1: Who are the primary manufacturers of CONJUPRI globally?
A1: The primary licensed manufacturers vary by region, but typically include the patent-holding company operating through regional licensed facilities. Specific manufacturers depend on licensing agreements and regulatory approvals.
Q2: How do regional regulations impact the supply of CONJUPRI?
A2: Regional regulations determine manufacturer licensing rights, influence approval timelines, and can restrict or enable the entry of generic versions, directly affecting supply availability.
Q3: Are generics available for CONJUPRI?
A3: Post-patent expiration, generic manufacturers may produce CONJUPRI, increasing supply options and reducing prices in certain markets.
Q4: What risks exist in sourcing CONJUPRI from regional suppliers?
A4: Risks include supply disruptions due to manufacturing issues, regulatory delays, or geopolitical factors affecting imports and distribution.
Q5: How can healthcare providers ensure consistent supply of CONJUPRI?
A5: By establishing agreements with multiple licensed regional suppliers, monitoring regulatory developments, and engaging with authorized distributors to preempt shortages.
References
- [1] U.S. Food and Drug Administration. Approved Drug Database. https://www.fda.gov
- [2] European Medicines Agency. Product Data. https://www.ema.europa.eu
- [3] National Medical Products Administration (NMPA), China. Approved Drugs Database.
- [4] Industry reports on ophthalmic pharmaceuticals, IQVIA.
- [5] Patent and licensing disclosures linked to CONJUPRI via company filings.
In conclusion, suppliers for CONJUPRI are primarily regional licensees, with manufacturing and distribution tightly governed by regulatory frameworks and patent rights. Stakeholders must monitor licensing agreements, regional approvals, and supply chain dynamics to secure consistent access and optimize procurement strategies.
More… ↓
